ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO914

Efficacy of COVID-19 Vaccination in Dialysis Patients: A Prospective Multicenter Study

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Ostermaier, Claudia, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Hessen, Germany
  • Kamalanabhaiah, Sahana R., Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Hessen, Germany
  • Haas, Christian Stefan, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Hessen, Germany
  • Keller, Christian, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Hessen, Germany
  • Hoyer, Joachim, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Hessen, Germany

Dialysis patients are considered to be at increased risk for SARS-CoV-2 infections. Thus, they were prioritized for early vaccination. However, early data suggested that seroconversion rates may be lower in this population, consistent with the reduced response rate to vaccination against hepatitis B, pneumococcus or influenza. The objective of this study was to evaluate the efficacy of COVID-19 vaccines in this cohort with respect to seroconversion, and to identify potential risk factors for nonresponding.


We conducted a prospective, multicenter study in chronic hemodialysis patients at 4 dialysis facilities in central Germany, starting April 2021. Blood samples were taken prior to 1st vaccination, before 2nd vaccination, 7-14 days after 2nd vaccination, as well as 60 and 120 days after full vaccination for long-term follow-up. At any study time point, results of COVID-19 antigen tests and clinical symptoms were assessed. Similarily, data was obtained for 1st or 2nd booster vaccination. Blood samples for antibody titers were drawn – if applicable – at day 30, 90, 150 and 210 following booster vaccination. To identify potential risk factors, data including underlying condition, comorbidities, lab results, seroresponse to hepatitis B vaccination, immunosuppression and other medication was assessed. Antibody response was defined above a value of 7.1 BAU/l.


After 2 vaccinations, 288 individuals were evaluated; of these, 270 (=93%) developed an adequate antibody response. Although the majority of patients had received a mRNA vaccine, there was no significant difference in the allover response rates compared to vector based vaccines. Age and immunosuppressive medication were found to be significant risk factors for nonresponsiveness to COVID-19 vaccination (p<0.05). Infections dropped following immunization. Of note, 6 months after full vaccination, antibody titers significantly declined. Both, 1st and 2nd booster doses resulted in an increase of antibody titers: during the omicron wave, no COVID-19 associated hospital admissions were observed.


COVID-19 vaccination is effective in hemodialysis patients. Like in the general population, only age and immunosuppression are risk factors for not responding to vaccination, thereby having a potential impact on outcome, especially for the wave to come.